169 related articles for article (PubMed ID: 36629931)
21. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
[TBL] [Abstract][Full Text] [Related]
22. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
23. Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
Mané M; Benkhaled S; Dragan T; Paesmans M; Beauvois S; Lalami Y; Szturz P; Gaye PM; Vermorken JB; Van Gestel D
Oncologist; 2021 Jan; 26(1):e130-e141. PubMed ID: 32924198
[TBL] [Abstract][Full Text] [Related]
24. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
25. Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Zhang J; Chen S; Li G; Zhang W; Qin T; Yin P; Huang H; Jiang H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1087-1097. PubMed ID: 28429051
[TBL] [Abstract][Full Text] [Related]
26. Induction chemotherapy followed by intensity-modulated radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma: A retrospective analysis.
He Y; Zhao Z; Wang Y; He J; Chai J; Wei Z; Guan H; Wang J; Liu Z; Li R; Mu X; He L; Peng X
Clin Otolaryngol; 2021 Sep; 46(5):976-982. PubMed ID: 33821552
[TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy in nasopharyngeal carcinoma- A systematic review of phase III clinical trials.
Nazeer F; Poulose JV; Kainickal CT
Cancer Treat Res Commun; 2022; 32():100589. PubMed ID: 35724627
[TBL] [Abstract][Full Text] [Related]
28. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced nasopharyngeal carcinoma: A retrospective propensity score matching analysis.
Tao HY; Zhan ZJ; Qiu WZ; Liao K; Yuan YW; Zheng RH
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e111-e118. PubMed ID: 33945215
[TBL] [Abstract][Full Text] [Related]
30. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
[TBL] [Abstract][Full Text] [Related]
31. Optimize the number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
Jiang Y; Chen K; Yang J; Liang Z; Qu S; Li L; Zhu X
J Cancer; 2022; 13(2):426-435. PubMed ID: 35069892
[No Abstract] [Full Text] [Related]
32. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
34. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
35. Positive effect of high RKIP expression on reduced distant metastasis by chemotherapy when combined with radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a prospective study.
Li SW; Wang H; Liu ML; Zhang HB; Xiang YQ; Lv X; Xia WX; Zeng MS; Mai HQ; Hong MH; Guo X
Med Oncol; 2013 Mar; 30(1):322. PubMed ID: 23254962
[TBL] [Abstract][Full Text] [Related]
36. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and toxicity of induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A meta-analysis of randomized controlled trials.
Wang P; Zhang M; Ke C; Cai C
Medicine (Baltimore); 2020 Mar; 99(10):e19360. PubMed ID: 32150078
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Huang PY; Cao KJ; Guo X; Mo HY; Guo L; Xiang YQ; Deng MQ; Qiu F; Cao SM; Guo Y; Zhang L; Li NW; Sun R; Chen QY; Luo DH; Hua YJ; Mai HQ; Hong MH
Oral Oncol; 2012 Oct; 48(10):1038-1044. PubMed ID: 22591726
[TBL] [Abstract][Full Text] [Related]
39. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
40. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]